Table 2.
Treatment outcomes for lobomycosis in French Guiana, 1959–2022.
| Treatment | Daily Dosage | Duration | Number | Therapeutic Response | Follow-Up Time after Treatment | ||
|---|---|---|---|---|---|---|---|
| Complete Response | Partial Response | Treatment Failure | |||||
| 5-Fluorocytosine | 100–150 mg/kg | 1–3 mths | 3 | 0 | 0 | 3 | 12 yrs |
| Sulfamethoxypyridazine | 500 mg | 1 mth | 1 | 0 | 1 | 0 | 7 yrs |
| Miconazole injection | 0.5 mL/inj/mth | 5 mths | 1 | 0 | 0 | 1 | 7 mths |
| Terbinafine | 500 mg | 2–6 mths | 2 | 0 | 0 | 2 | 6 mths |
| Terbinafine + Surgical excision |
500 mg | 2 mths | 1 | 1 | 0 | 0 | 12 yrs |
| Itraconazole | 200–400 mg | 1–4 mths | 3 | 0 | 0 | 3 | 1–4 mths |
| Itraconazole Clofazimine + Surgical excision |
400 mg 100 mg |
1 mth | 1 | 0 | 0 | 1 | 3 yrs |
| Posaconazole | 800 mg | 18 mths | 1 ** | 0 | 1 | 0 | 18 mths |
| MDT * | - | 1–12 mths | 3 ** | 0 | 1 | 2 | 12 mths |
| Total | 16 | 1 | 3 | 12 | |||
* Multiple drug therapy consisted of monthly supervised doses of 600 mg rifampicin, 300 mg clofazimine, and 100 mg dapsone, in addition to daily doses of 50 mg clofazimine and 100 mg dapsone. ** second-line therapy.